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Abstract
The Epithelial-to-mesenchymal transition (EMT) is a cell-biological program that confers 
mesenchymal traits on carcinoma cells and drives their metastatic dissemination. It is, unclear, 
however, whether activation of EMT in carcinoma cells can change their susceptibility to immune 
attack. We demonstrate here that mammary tumor cells arising from more epithelial carcinoma 
cell lines expressed high levels of MHC-I, low levels of PD-L1 and contained within their stroma 
CD8+ T cells and M1 (anti-tumor) macrophages. In contrast, tumors arising from more-
mesenchymal carcinoma cell lines exhibiting EMT markers expressed low levels of MHC-I, high 
levels of PD-L1 and contained within their stroma regulatory T cells, M2 (pro-tumor) 
macrophages and exhausted CD8+ T cells. Moreover, the more mesenchymal carcinoma cells 
within a tumor retained the ability to protect their more epithelial counterparts from immune 
attack. Lastly, epithelial tumors were more susceptible to elimination by immunotherapy than 
corresponding mesenchymal tumors. Our results identify immune cells and immunomodulatory 
markers that can be potentially targeted to enhance the susceptibility of immunosuppressive 
tumors to various therapeutic regimens.
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INTRODUCTION
The microenvironment of breast carcinomas is enriched with immunosuppressive cells that 
interact with carcinoma cells via a variety of heterotypic signaling mechanisms (1, 2). 
However, the factors that contribute to immunosuppression in the tumor microenvironment 
are poorly defined. The Epithelial to Mesenchymal Transition (EMT) is a cell-biological 
program that drives the metastatic dissemination of carcinomas including breast cancers 
(BrCa). After activation of an EMT, carcinoma cells begin to secrete a distinct cohort of 
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cytokines such as TGF-β (3). TGF-β is required for the formation of immunosuppressive 
Tregs and reduces the cytotoxicity of natural killer (NK) cells (4, 5). It remains unclear, 
however, whether immunosuppression occurs as a direct consequence of the EMT program 
or develops through the mediation of additional, still-uncharacterized signaling channels. 
Moreover, carcinoma cells that have undergone an EMT are more refractory to various 
chemotherapeutic regimens (6). However, whether carcinoma cells residing in the epithelial 
versus mesenchymal state mount distinct responses to checkpoint blockade therapy is 
unknown. For these reasons, we undertook to understand the dynamics of the 
microenvironmental interactions of breast cancers cells that remain in a largely epithelial 
state or have acquired mesenchymal characteristics following activation of an EMT 
program.
MATERIALS AND METHODS
Mice
C57BL/6 mice were obtained from the Jackson laboratory. A colony of NOD-SCID mice 
was generated and maintained in-house. All animals used for experiments were 6–8 week 
old female mice. Animals were maintained in compliance with the guidelines and protocols 
approved by the Animal Care and Use Committees at the Massachusetts Institute of 
Technology.
Cell lines and cell culture
PyMT tumor cell lines from which epithelial (pB-2) and mesenchymal (pB-3) versions were 
derived, were kind gifts from the Harold L. Moses laboratory and were established and 
maintained as described previously (7). Cells were cultured in DMEM/F12 medium 
containing 5% adult bovine serum with 1X penicllin-streptomycin and 1X non-essential 
amino acids for the duration of this study. MCF7 and T47D cell lines were obtained from 
ATCC and established and maintained as previously described (8) in DMEM supplemented 
with 10% fetal bovine serum and 1X penicllin-streptomycin. Cells tested negative for 
mycoplasma (2014) and were not authenticated since first acquisition. All cell lines were 
obtained between 2009–2012 and used within 2–3 years since first acquisition. Cells were 
stably transfected with GFP, RAS or doxycycline-inducible EMT-TFs as previously 
described (8, 9). All cell lines containing doxycycline-inducible expression vectors were 
treated with 1.5 μg/ml (PyMT) or 1 μg/ml (MCF7RAS and T47DRAS) doxycycline hyclate 
(Sigma Aldrich).
In vivo models and tumor dissociation
For orthotopic tumor transplantations, sorted cell populations – EpCAMHI (epithelial PyMT 
cell line-pB-2), EpCAMLO(mesenchymal PyMT cell line-pB-3), EpCAMHISnail-YFPLO 
(Snail-lo) and EpCAMLOSnail-YFPHI (Snail-hi) were resuspended in 30μl media containing 
20% Matrigel. 1 × 106 cells were implanted into the mammary fat pads of C57BL/6 or 
NOD/SCID mice. Animals were sacrificed once tumors reached 2cm in size. Tumors were 
excised and divided into two parts. One part was digested and used for flow cytometry 
analysis and the other part was fixed in formalin for tissue sections. For tumor digestions, 
tumors were minced with a razor blade and digested in RPMI containing 2mg/ml 
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collagenase and 100 units/ml hyaluronidase (Roche) in a rotator at 37°C for 1hr. Dissociated 
tumors were washed two times in PBS and filtered through a 70 μm and 40 μm cell strainer 
to obtain single-cell suspensions. For immunotherapy experiments, mice bearing tumors 
arising from various cell lines were treated with anti-CTLA4, 200 ug, clone 9H10, every 
three days for 20 days.
Flow cytometry
Dissociated tumors were resuspended in wash buffer (PBS containing 0.1% BSA) and 
stained for surface markers using CD45 PECy7 (30F-11; Affymetrix), CD45 FITC (30F-11; 
Affymetrix), CD4 PE (RM4-5; Affymetrix), CD8a APC (53-6.7; Affymetrix), CD25 
PercpCy5.5 (pc61.5; Affymetrix), CD44 PercpCy5.5 (IM7; Affymetrix), PD-1 FITC (J43; 
Affymetrix), CTLA4 PE (UC10-4B9; Affymetrix), CD107a PercpCy5.5 (1D4B; 
Affymetrix), CD11B PercpCy5.5 (M1/70; Affymetrix), F480 PECY7 (BM8; Affymetrix), 
LY6C E450 (HK1.4; Affymetrix), LY6G APC (1A8; Affymetrix), CD206 APC (MR6F3; 
Affymetrix), CD3 PercpCy5.5 (17A2; Affymetrix), NK1.1 PE (PK136; Affymetrix), MHC I 
(H-2Kb) PE (AF6-88.5.5.3; Affymetrix), CD274 BV605 (10F.9G2; Biolegend), HLA-ABC 
APC (W6/32; Affymetrix), PDL1 FITC (MIH1; BD Biosciences). CD8+ T-cells were sorted 
from digested tumor samples and co-cultured with the respective PyMT cells (1 × 106 cells/ 
ml) for 5 hrs in the presence of Monensin Golgi Stop (BD Biosciences). Intracellular 
cytokine staining was performed using the Intracellular Fixation and Permeabilization 
Buffer Set (Affymetrix). Intra-cellular staining for FOXP3 was performed using the FOXP3/
Transcription Factor Staining Buffer Set (Affymetrix) using FOXP3 Alexa488 (FJK-16s; 
Affymetrix), NOS2 FITC (CXNFT; Affymetrix), IL-12 PE (C15.6; Biolegend), IFNγ 
PECY7 (XMG1.2; Affymetrix). Flow cytometry data was acquired on a BD LSRFortessa 
and data was analyzed using the FlowJo (TreeStar) software.
Western Blot
Whole cell lysates were made in RIPA Buffer (150mM NaCl, 1% IgeCal-CA 360, 0.1% 
SDS, 50mM Tris, pH-8.0, 0.5% Sodium deoxycholate) and resolved on a gradient gel. 
Protein was transferred on a nitro-cellulose membrane and blocked in 5% milk powder and 
0.2% Tween-20 in PBS. Membranes were probed over-night with primary antibody, washed 
and incubated with horseradish peroxidase (HRP) labeled secondary antibody and developed 
using ECL substrate (ThermoFisher). Primary antibodies used were E-cadherin, Vimentin, 
Zeb1, Snail, GAPDH, β-tubulin, β2-microglobulin (Cell Signaling Technology), Fibronectin 
(BD Biosciences), Twist (Abcam).
Immunofluorescence Staining
Tumors were fixed in 10% neutral buffered formalin for12–24 hrs and transferred to 70% 
ethanol, followed by embedding and sectioning. Tumor sections were washed two times in 
Histoclear II, followed by one wash each in 100%, 95%, 75% ethanol, PBS and 1X wash 
buffer (Dako). Antigen retrieval was done in 1X Target Retrieval Solution, pH 6.1 (Dako) in 
a microwave. Sections were blocked in PBS containing 0.3% Triton-X100 and 1% normal 
donkey serum (Jackson ImmunoResearch Laboratories) for 1hr at room temperature. 
Sections were incubated with primary antibody at 4°C, overnight. Sections were washed two 
times in 1X wash buffer followed by incubation with secondary antibody (Biotium) for 2 
Dongre et al. Page 3
Cancer Res. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hrs. Sections were washed three times with 1X wash buffer and incubated with DAPI for 10 
mins, followed by 1 wash in PBS. Sections were mounted using Prolong gold antifade 
reagent (Invitrogen). Tumor cell lines were fixed in 2.5% neutral buffered formalin on ice 
for 15 mins, followed by three washes in PBS+. Cells were fixed in Triton-X100 for 3 mins 
and blocked in PBS- containing 3% normal donkey serum. Cells were incubated with 
primary antibody at 4°C, overnight. Cells were washed three times with PBS- followed by 
incubation with secondary antibody 2 hrs. Cells were washed three times with PBS- and 
incubated with DAPI for 10 mins, followed by 1 wash in PBS. Cells were mounted using 
Prolong gold antifade reagent. Primary antibodies used were E-cadherin (BD Biosciences), 
Vimentin (Cell Signaling Technology), Zeb1 (Santa Cruz Biotechnology), CD3 (AbCam), 
CD8 (Abbiotec), F480 (ThermoFisher), Arginase1 (Santa Cruz Biotechnology). Images 
were acquired using the Zeiss confocal microscope and analyzed using the Zen software.
Statistical Analysis
All data are represented as mean +/− SEM. Statistical Analysis was performed using the 
GraphPad Prism software. P values were calculated using an unpaired two-tailed student’s t 
test. * p<0.05, ** p<0.01, *** p<0.001, ns – not significant.
RESULTS
To determine whether the immune responses to epithelial and mesenchymal carcinoma cells 
were fundamentally different, we used cell lines that were established from tumors arising in 
the transgenic MMTV-PyMT mouse model of breast adenocarcinoma development (7). 
Some of these cell lines were more epithelial and expressed high levels of E-cadherin and 
EpCAM, whereas others were more mesenchymal and in contrast expressed vimentin, low 
levels of EpCAM, and significant levels of the Zeb1, Twist and Snail EMT-inducing 
transcription factors (EMT-TFs) (Fig 1A, Supplementary Fig 1A, B).
To determine whether tumors formed from the epithelial and mesenchymal cell lines were 
differentially susceptible to immune attack, we implanted these cells orthotopically into 
syngeneic immunocompetent hosts. Tumors arising from the more-epithelial cell line were 
well-differentiated adenocarcinomas and expressed E-cadherin, while tumors arising from 
the more mesenchymal cells were poorly differentiated, exhibited a sarcomatoid 
histomorphology, and expressed instead the mesenchymal marker vimentin (Fig 1A).
Most strikingly, the stroma of primary tumors arising from the more mesenchymal cell line, 
relative to those spawned by the more epithelial carcinoma cells, contained significantly 
higher numbers of CD25+ FOXP3+ Tregs and lower numbers of CD25+ FOXP3− effector 
CD4+ T-cells (Fig 1B, Supplementary Fig 1D). Conversely, tumors arising from the 
epithelial cell line contained higher numbers of CD8+ cytotoxic T-cells instead (Fig 1B, 
Supplementary Fig 1C). Furthermore, a higher percentage of CD8+ T-cells present in the 
stroma of epithelial tumors expressed CD107a, Perforin, Granzyme b and IFN-γ compared 
to those present in mesenchymal tumors, indicative of effector function (Fig 1B). Finally, the 
few CD8+ T-cells present in the stroma of the more mesenchymal tumors co-expressed 
markers associated with functional exhaustion, PD-1 and CTLA4 (Fig 1B).
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Tumors arising from the more mesenchymal cell lines also contained a significantly higher 
number of macrophages that expressed the mannose receptor CD206 and stained positive for 
Arginase1, indicating a pro-tumor M2 phenotype, relative to the macrophages present in 
tumors arising from the more epithelial cells, which by contrast did not express either of 
these two markers but instead stained positively for iNOS and IL-12, markers of M1, anti-
tumor macrophages (Fig 1C, Supplementary Fig 1E–F).
Immunofluorescence analysis of tumor sections revealed that CD3+ and CD8+ T-cells had 
infiltrated the tumors arising from the epithelial cell line, while the macrophages remained 
largely at the periphery. This contrasted with tumors arising from the mesenchymal cell line, 
which were infiltrated by macrophages (Fig 1D). We did not however, observe any 
significant differences in the numbers of monocytic or granulocytic MDSCs infiltrating 
these two classes of tumors (Supplementary Fig 1G, H). These results indicated that, in 
contrast to the stroma assembled by the more-epithelial tumors, the stroma of tumors arising 
from the more-mesenchymal cells, was largely immunosuppressive.
Using MMTV-PyMT reporter mice that bear knock-in IRES-YFP constructs reporting the 
activity of the endogenous Snail and Slug promoters, we recently demonstrated that, when 
expressed at physiologic levels, Snail is associated with a CSC-like phenotype, whereas Slug 
choreographs the normal mammary epithelial stem cell state (7). To determine whether the 
Snail-expressing carcinoma cells would also be immunosuppressive, we sorted cells that 
differed in their expression of the Snail-YFP reporter and thus endogenous Snail protein, 
from tumors arising in MMTV-PyMT-Snail-YFP mice using YFP expression in conjunction 
with EpCAM, as previously described (Supplementary Fig 2A and (7)). Snail-hi-YFP cells 
were mesenchymal and did not express any epithelial markers, but expressed instead N-
cadherin, vimentin, fibronectin and the Zeb1 EMT-TF. In contrast, Snail-lo-YFP cells were 
less mesenchymal and expressed high levels of both EpCAM and E-cadherin and low levels 
of Zeb-1 (Fig 2A, Supplementary Fig 2B). This approach allowed us to compare the immune 
response to related cell lines, which were established from the same tumor and differed in 
their levels of Snail expression.
Tumors arising from orthotopic implantation of the Snail-lo cells were heterogeneous and 
contained some sectors of E-cadherin-expressing cells. In contrast, Snail-hi tumors were 
poorly differentiated and lacked E-cadherin expression (Fig 2A). Although we did not 
observe any difference in the numbers and function of CD8+ T-cells (Fig 2B, Supplementary 
Fig 2C), Snail-hi tumors exhibited a significantly higher percentage of infiltrating Tregs (Fig 
2B, Supplementary Fig 2D), and an increase in CD206-expressing M2-macrophages (Fig 
2C, Supplementary Fig 2E–F), relative to Snail-lo tumors. These macrophages also 
expressed Arginase1, in contrast to Snail-lo tumors, which lacked Arginase1-expressing 
macrophages (Fig 2C). Furthermore, these macrophages had infiltrated Snail-hi tumors, 
which was in sharp contrast to Snail-lo tumors, where the macrophages were confined 
largely at the tumor periphery (Fig 2D). Conversely, Snail-lo tumors were infiltrated by 
CD3+ and CD8+ T-cells (Fig 2D). Additionally, adenocarcinomas arising from another 
epithelial cell line established from Slug reporter mice (7), (Supplementary Fig 3A–B) were 
also infiltrated by significantly higher numbers of CD8+ T-cells and significantly fewer 
numbers of Tregs and M2 macrophages relative to Snail-hi cells (Supplementary Fig 3C–H). 
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Once again these observations demonstrated that more mesenchymal Snail-hi cells were 
capable of inducing a tumor microenvironment rich in immunosuppressive Tregs and M2 
macrophages in contrast to the less mesenchymal Snail-lo cells.
We also observed that the more mesenchymal cell lines, which clearly recruited 
immunosuppressive cells to the tumor-associated stroma, showed a striking reduction in the 
levels of surface MHC-I compared to the more epithelial cell lines (Supplementary Fig 4A–
D). Furthermore, tumors arising from the more mesenchymal carcinoma cell lines in both 
immune-competent and immune-deficient mice, exhibited significantly fewer MHC-I+ cells 
compared to those arising from the epithelial cell lines. In contrast, we found that tumors 
arising from the more mesenchymal carcinoma cell lines contained instead a higher 
percentage of PD-L1- positive cells (Supplementary Fig 4E–H). Of note, activation of an 
EMT in epithelial cell lines by forced expression of various doxycycline-inducible EMT-TFs 
(Supplementary Fig 5A–C) resulted in a decrease in protein levels of MHC-I expression, 
which was also accompanied by decreased expression of β2-microglobulin (β2M) 
(Supplementary Fig 5D, F, H) and increased expression of PD-L1 (Supplementary Fig 5E, 
G). Thus, the immunoevasive and immunosuppressive maneuvers assembled by the 
carcinoma cells resulted directly from the cell-autonomous actions of the EMT program.
Carcinomas of the type studied here are comprised of heterogeneous mixtures of both 
epithelial and mesenchymal cells. However, it was unclear whether the minority 
subpopulations of immunosuppressive mesenchymal carcinoma cells are able to protect the 
entire tumor including its epithelial cells from immune attack or whether, their 
immunosuppressive effects were limited to their immediate vicinity. To address this 
question, we injected mixtures of unlabeled epithelial cells with two different GFP-labelled, 
mesenchymal cell lines described earlier.
We observed that a decrease in the proportion of epithelial cells (10:1, 4:1 and 1:1 ratio of 
E:M cells) was accompanied by a concomitant decrease in the number of infiltrating CD8+ 
T-cells (Fig 3A and Supplementary Fig 6A, C). CD8+ T-cells present in these various co-
mixed tumors did not show any reduction in the expression of markers associated with 
effector function compared to those present in tumors arising exclusively from epithelial 
cells. Nonetheless, the CD8+ T-cells that were present in all three types of co-mixed tumors 
co-expressed PD1 and CTLA4, indicative of partial exhaustion, relative to CD8+ T-cells 
present in tumors arising only from epithelial cells (Fig 3A and Supplementary Fig 6A). In 
sharp contrast, a decrease in the proportion of epithelial cells in all co-mixed tumors was 
accompanied by an increase in the number of suppressive Tregs (CD25+ FOXP3+) (Fig 3A 
and Supplementary Fig 6A, C) and a decrease in the number of CD4+ effector T-cells 
(CD25+ FOXP3− and CD44+ FOXP3−) (Fig 3B and Supplementary Fig 6B).
Similarly, macrophages present in all types of co-mixed tumors expressed pro-tumor M2 
markers CD206 and Arginase1 and low levels of the iNOS anti-tumor, M1 marker, relative 
to macrophages present in tumors arising from the epithelial cells alone (Fig 3B, 
Supplementary Fig 6B, C). Hence even when the mesenchymal cells were present as small 
minority subpopulations (~10%), they were nonetheless able to influence the numbers of 
suppressive Tregs and M2 macrophages in the tumors as a whole.
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Both immunofluorescent and H&E staining of tumors arising from the mixtures of cells 
injected in different ratios revealed that the epithelial and mesenchymal cells became 
segregated to distinct sectors of the tumor and thus did not physically intermingle (Fig 3C– 
top, Supplementary Fig 6D). Additionally, mesenchymal sectors within the co-mixed tumors 
continued to express features associated with the EMT such as vimentin and nuclear Zeb1, 
in contrast to their epithelial counterparts, which expressed E-cadherin instead (Fig 3C- 
middle, bottom, Supplementary Fig 6D).
This clear segregation of the two types of tumor cells to distinct sectors of tumors allowed us 
to examine the topological relationships between recruited immune cells and readily 
identifiable epithelial and mesenchymal sectors of the tumors. As we found, CD8+ T-cells 
were found near the epithelial sectors of mixed tumors. Conversely, numerous Arginase1+ 
F480+ M2-macrophages were interspersed only among the GFP-positive, mesenchymal cells 
of the tumor, while only a few scattered macrophages were found at the periphery of 
epithelial sectors within the same tumor (Fig 3D – top, Supplementary Fig 6E). Most 
importantly, the latter macrophages did not stain positive for Arginase1 (Fig 3D – middle), 
indicating that the juxtaposition of macrophages with mesenchymal but not epithelial cells 
within a tumor was likely to be crucial for regulating their immunosuppressive function. 
These data suggest that the proportion of mesenchymal cells dictates the numbers and types 
of suppressive immune cells recruited to the tumor.
Having observed substantial differences in T-cells infiltrating the primary tumors arising 
from implanted epithelial versus mesenchymal carcinoma cells, we asked whether these 
tumors would differ in their susceptibility to checkpoint blockade therapy (10, 11). While 
epithelial tumor bearing mice showed a complete response to anti-CTLA4 immunotherapy, 
mesenchymal-tumor bearing mice were refractory to treatment (Fig 4A, B). Interestingly, 
tumors arising from 1:1 or 9:1 mixtures of epithelial and mesenchymal cells respectively, 
also did not respond to anti-CTLA4 treatment (Fig 4C). Additionally, anti-CTLA4 treatment 
did not alter the numbers or EMT-features of epithelial and mesenchymal cells within mixed 
tumors (Supplementary Fig 7A, B). Hence, these data suggest that the immunosuppressive 
tumor microenvironment of mesenchymal tumors made them resistant to elimination via 
check-point blockade therapy (12, 13). Moreover, the presence of even a small minority of 
mesenchymal carcinoma cells resulted in the loss of responsiveness of tumors to checkpoint 
blockade therapy.
DISCUSSION
Several studies have demonstrated an association between the EMT and immunosuppression 
in other cancer types following forced expression of EMT-TFs (12). However, high-level 
expression of EMT-TFs elicits functional changes in carcinoma cells that do not recapitulate 
the changes occurring when these EMT-TFs are expressed under cell-physiologic control. 
(7). This explains why we undertook the presently described work to determine whether an 
association between the EMT and immunosuppression does indeed occur when EMT-TFs 
are expressed under physiologic control using cell lines that were established directly from 
tumors arising in MMTV-PyMT mice.
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Mesenchymal cell lines and the tumors arising from them expressed markedly lower levels 
of cell-surface MHC-I compared to epithelial cell lines and their corresponding tumors, 
raising the question of whether such MHC-I-low expression levels render tumor cells 
vulnerable to NK-mediated killing (14). Indeed, we did observe a higher percentage of NK 
cells infiltrating MHC-I-low tumors arising from mesenchymal cell lines relative to MHC-I-
high tumors arising from epithelial cell lines (Supp Fig 1E and 2E). Importantly, however, 
these tumors were not eliminated despite the presence of such NK cells. We attribute this 
outcome to the actions of other immunosuppressive subsets, such as Tregs, which were 
present abundantly in mesenchymal tumors and are known to dampen NK function (4, 15).
The presence of cytotoxic lymphocytes in MHC-I expressing epithelial tumors is likely to 
make them more susceptible to elimination via checkpoint blockade therapy. Indeed, 
patients with tumor-infiltrating lymphocytes (TILs) generally have a relatively good 
prognosis and are thought to generate favorable responses to checkpoint blockade treatment 
regimes (10, 16). In contrast, the strongly immunosuppressive stroma of mesenchymal 
tumors may render them refractory to such therapy (13).
Our studies demonstrate that epithelial and mesenchymal carcinomas differ in their 
susceptibility to immune attack. Although we have yet to determine the precise molecular 
mechanism(s) by which EMT-induced immunosuppression takes place, we suggest that this 
may likely occur by several mechanisms. Among these are dysregulated expression of 
immunomodulatory markers associated with immune-evasion and alterations in cytokine and 
chemokine secretion patterns, which may act as the first step that triggers a cascade of 
events that ultimately culminate in immunosuppression. All of these immunoevasive 
maneuvers utilized by carcinoma cells could act in concerted fashions to (i) recruit specific 
immunosuppressive cells to the tumor microenvironment and/or (ii) reprogram pre-existing 
cells to adopt an immunosuppressive phenotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Immunosuppressive cells in tumors arising from mesenchymal cell lines
(A) Western blot for EMT markers expressed by cell lines. Haemotoxylin and Eosin and (B, 
D) Immunofluorescent staining of tumor sections for the indicated markers (N=5). Scale bar, 
100 μm. (B, C) Digested tumors were analyzed for the indicated immune populations by 
flow cytometry after gating on CD45+ cells. Data represent three independent experiments
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Fig 2. Immunosuppressive cells in tumors arising from Snail+ cells
(A) Western blot for EMT markers. Haemotoxylin and Eosin and (C, D) Immunofluorescent 
staining of tumor sections for the indicated markers (N=5). Scale bar, 100 μm. (B, C) 
Digested tumors were analyzed for the indicated immune populations by flow cytometry 
after gating on CD45+ cells. Data represent three independent experiments.
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Fig 3. Ability of mesenchymal cells to protect epithelial cells from immune attack
(A, B) Digested tumors were analyzed for the indicated immune populations by flow 
cytometry after gating on CD45+ cells. (C) Haemotoxylin and Eosin and (C, D) 
Immunofluorescent staining of tumor sections for the indicated markers. (N=5). Scale bar, 
100 μm. Data represent three independent experiments.
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Fig 4. Response of Epithelial and Mesenchymal tumors to immunotherapy
(A, B, C) Average tumor growth of mice that did or did not receive anti-CTLA4 therapy. 
Data represent three independent experiments.
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